Aethlon Medical, Inc. (OTCMKTS:AEMD) Stumbles Despite Positive News

[[tagnumber 0]][[tagnumber 1]]Aethlon Medical, Inc. (OTCMKTS:AEMD) is one of the companies that received a lot of attention after the ebola epidemic hit the news and its share price has almost tripled since the start of October, while the volumes of traded stock have also increased.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]AEMD [[tagnumber 7]]did receive a lot of attention in the first session of the week after more precise results of the role of their [[tagnumber 6]]Hemopurifier® [[tagnumber 7]]in the case of the Ugandan physician treated in Frankfurt came to surface.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The ticker exploded and added a decent 28.44% to its value on Monday while generating a massive $13.55 million in daily dollar volume. Let’s not forget that these positive results coupled with the decent financial state of the company are perfectly capable of generating that much investor attention.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Here is a reminder of the latest financial report that was filed a week ago and covered the period ended September 30.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 21]] [[tagnumber 22]]cash: $526 thousand[[tagnumber 23]] [[tagnumber 22]]current assets: $892 thousand[[tagnumber 23]] [[tagnumber 22]]total assets: $1 million[[tagnumber 23]] [[tagnumber 22]]current liabilities: $3.38 million[[tagnumber 23]] [[tagnumber 22]]total liabilities: $4.37 million[[tagnumber 23]] [[tagnumber 22]]quarterly revenues: $479 thousand[[tagnumber 23]] [[tagnumber 22]]net loss: $847 thousand[[tagnumber 23]] [[tagnumber 36]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Even more good news came yesterday, as SeeThruEquity raised their price target for [[tagnumber 6]]AEMD [[tagnumber 7]]from $0.52 to $0.74, but unfortunately the ticker rebounded and lost 11.90%, while it closed at $0.37, with a daily dollar volume of $7.37 million.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Just before today’s session, however, [[tagnumber 6]]AEMD [[tagnumber 7]]came out with a press release that they will provide their [[tagnumber 6]]Hemopurifier®[[tagnumber 7]] under FDA’s expanded access “[[tagnumber 50]]emergency use[[tagnumber 51]]” provisions to treat patients in the US. So far, these news have had a positive impact and by the writing of this article the ticker is sitting 12.63% higher at $0.41.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the fact that [[tagnumber 6]]AEMD[[tagnumber 7]] can still slide, despite positive news and the market cap of $121 million that doesn’t match the book value at all should be enough reason for you to do your due diligence and weigh out the risks before making an investment decision.[[tagnumber 2]]